Project 2. Program CJirector/Principal Investigator (Last, First. Middle): G A R C I A - S A S T R E , A d o l f o PROJECT SU^/)^MRY (See instructions): Work in Project 2 will explore exciting recent developments in the study of cross-reactive immunity to influenza viruses.The goal of this project is to determine the molecular and structural basis for broadly erbss-reactive human mAb responses to influenza HAs;As the epitope sequences and structures reccjgnized by broadly cross-reactive Abs are defined, we will be better able to rationally design broadly protective immuriogens. The work seeks to investigate the repertoire of human Abs recognizing three principal Gonserved regions of the HA molecule;a canonical stalk domain epitope, the long alpha-helix stalkdomain, and the globular head domain. The hypothesis is that, unexpectedly, there are at least three immunogenic domains in influenza HA that retain highly conserved structural features and that most adult healthy subjects do possess circulating cross-reactive B cell clones to these conserved sites on HA. These domains are complex, however, and relatively inaccessible-for conventional Ab structures, w e have developed robust technologies for isolating human mAbs that reveal the relatively frequent nature of eross-reactive B ceils, and the genetic'arid structural basis for broad cross-reactivity of the secreted Abs for influenza viruses of diverse subtypes. We hypothesize that such cross-reactivity is driven by unusual features in the Ab repertoire^ especially an exceptionally high levefof somatic point mutations and somatic insertions. This highly interactive project will engage in collaborative work with Project 1 to determine mAb-HA co-crystal structures. Project 4 to study the biology of viral escape mutant viruses,; Project 5 to examine the effect of mutants on DCs, and will use the Glycan Array core to study glycosyiation in escape sites and the Animal Core to determine in vivQ potency of antibodies. Studies of such Abs and the sites recognized by them will inform the rational design of universalinfluenza vaccines based on the underlying principles of heterosubtypjc immunity;The stalk domain is of interest because highly eross-reactive Ab have been identified that recognized a conserved region in this area. However, the rare Abs identified to date do not possess both group 1 and 2 specificities, , In preliminary datBi we show that it is possible to isolate such Abs. Using these unusual reagents, we will define the basis for the group determinants or conserved elelmentS: by mapping the interaction of large panels of new Abs to the: stalk;region. We also will seek to isolate novel human Abs from human subjects that recognize the stalks of both major HA antigenic groijps. The head domain is better studied, however there are only rare Abs:that exhibit cross-reactiyity for ahtigenically distinct HAs. By large-scale sci-efening of B cells from subjectis immunized with seasonal and experimental vaccines, we have identified cross-reactive Abs that i-ecdgnize the head domain of HAs of multiple subtypes of influenza. By epitope mapping using biochemical arid biologic studies, coupled with studies to determine co-crystal stuctures, we will determine the structural basis for cross reactivity. RJELEVANGE (See instructions): Antibodies are the priricipal mediators of protection.induced against disease due to influenza following infection or vaccination, but influenza viruses exhibit a large amount of diversity, necessitating yearly vaccination. Some unusual human antibodies, however, react against a wide variety of influenza viruses, suggesting that;a! universal vaccine might be possible. The proposed studies will identify potential components of a universal vaccine antigen.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-MMT-M (J1))
Program Officer
Hauguel, Teresa M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Bangaru, Sandhya; Nieusma, Travis; Kose, Nurgun et al. (2016) Recognition of influenza H3N2 variant virus by human neutralizing antibodies. JCI Insight 1:
Thornburg, Natalie J; Zhang, Heng; Bangaru, Sandhya et al. (2016) H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. J Clin Invest 126:1482-94
Hooper, Kathryn A; Crowe Jr, James E; Bloom, Jesse D (2015) Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice. J Virol 89:3737-45
Winarski, Katie L; Thornburg, Natalie J; Yu, Yingchun et al. (2015) Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Proc Natl Acad Sci U S A 112:9346-51
Briney, Bryan S; Willis, Jordan R; Finn, Jessica A et al. (2014) Tissue-specific expressed antibody variable gene repertoires. PLoS One 9:e100839
Thornburg, Natalie J; Nannemann, David P; Blum, David L et al. (2013) Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J Clin Invest 123:4405-9
Xu, Rui; Krause, Jens C; McBride, Ryan et al. (2013) A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol 20:363-70
Finn, Jessica A; Crowe Jr, James E (2013) Impact of new sequencing technologies on studies of the human B cell repertoire. Curr Opin Immunol 25:613-8
Hong, Minsun; Lee, Peter S; Hoffman, Ryan M B et al. (2013) Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. J Virol 87:12471-80